American Journal of Clinical Oncology · 2007 · 89 citations · 7 references
Sorafenib shows clinical benefit without adversely impacting overall QOL and has a positive impact on some individual symptoms and concerns. These findings are consistent with other clinical results from this trial of advanced renal cell carcinoma patients treated with sorafenib, which included significantly greater progression-free survival and low risk for treatment limited toxicities.
7
Bernard Escudier, Cezary Szczylik, Tim Eisen et al. · Journal of Clinical Oncology · 2005 · 350 citations
Urology, Vegfr Inhibitor Sorafenib, Genitourinary Cancer +13